Clinical effects of gastrodin injection combined with fluoxitine in the treatment of post-stroke depression
10.3760/cma.j.issn.1008-6315.2013.07.022
- VernacularTitle:天麻素注射液联合盐酸氟西丁治疗卒中后抑郁的临床效果观察
- Author:
Haipeng WANG
;
Chunyu WANG
;
Jie LIU
;
Donghua LI
;
Chuming JANG
- Publication Type:Journal Article
- Keywords:
Gastrodin;
Stroke;
Post-Stroke;
Depression
- From:
Clinical Medicine of China
2013;(7):734-736
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effects and adverse reaction of Gastrodin Injection combined with Fluoxitine (Prozac) in the treatment of post-stroke depression (PSD).Methods One hundred and two patients with PSD were randomly allocated into two groups:51 cases in the Gastrodin Injection and Fluoxitine combination group (treatment group),51 cases in Fluoxitine Group (control group).The treatment group was treated by intravenous injection of 600 mg/d Gastrodin (14 days) plus oral administration of 20 mg/d Fluoxitine (30 days).The control group was only treated by oral administration of 20 mg/d Fluoxitine (30 days).The therapeutic effects were evaluated by the observations of the changes of symptoms and signs and Hamilton Depression Scale (HAMD) respectively in the two groups.Results The cured,effective,improved and invalid rates were 9.8% (5/51),52.9% (27/51),27.5% (14/51) and 9.8% (5/51) respectively in the treatment group and 2.0% (2/51),11.7% (6/51),66.7% (34/51) and 19.6% (10/51) in the control Group.The total effective rate in the treatment and the control groups were 90.2% (46/51) and 80.4% (41/51) respectively.The therapeutic effect was better in the treatment group than in the control group,and there was significant difference observed between the two groups (x2 =13.03,P < 0.05).The rate of adverse reaction was significantly lower in the treatment group than in the control group (3.92% (2/51) vs.25.5% (13/51),x2 =9.64,P < 0.01).Conclusion Gastrodin Injection in combination of Fluoxitine,with low adverse reation rate,is an effective therapeutic method for the treatment of PSD.